SCH58500 ( ACN53 ) is a replication -deficient, type 5 adenovirus ( Ad ) expressing human wild -type p53 tumor suppressor. It is currently undergoing clinical trials as a cancer therapeutic. Many SCH58500 clinical trials incorporate an arm comparing traditional chemotherapy against chemotherapy combined with SCH58500. Paclitaxel was chosen for combination therapy in the preclinical study reported here due to its extensive use as a first -line therapy in ovarian cancer, its synergy with SCH58500 in preclinical cancer models, and its activation of p53 -independent apoptosis, which might result in a``lowered threshold'' for tumor cell death. SCID mice bearing human tumor xenografts were dosed with intratumoral vehicle, control Ad vector, or SCH58500, with or without paclitaxel. Real -time quantitative reverse transcriptase polymerase chain reaction assays were developed and validated to quantitate expression of p53, the p53 downstream effector gene p21, and the apoptosis -related genes, bax, bcl -2, and survivin. Protein expression was confirmed using immunohistochemical assays for p53 and p21. Only tumors injected with SCH58500 had detectable levels of exogenous p53 DNA and mRNA. After SCH58500 treatment, 3 ± 11 ± fold elevations of p21 expression were observed in tumor xenografts containing nonfunctional p53 ( MDA -MB -468, MDA -MB -231, MIAPaCa2, DU -145, and SK -OV -3 ) , but no change in p21 mRNA in wild -type p53 PA -1 tumors. Immunohistochemical assays confirmed induction of p21 protein in MDA -MB -468 and SK -OV -3 cells, but not in PA -1 cells. Ad vector alone or paclitaxel alone had no effect on p21 mRNA levels in most tumors. However, paclitaxel suppressed p21 expression induced by SCH58500 4 -fold in DU -145 and SK -OV -3 tumors. Paclitaxel also affected expression of the housekeeping gene gapdh. There was no consistent pattern to the changes in bax, bcl -2, or survivin after SCH58500 treatment with or without paclitaxel between tumor types, although there were consistent responses within individual tumor lines. The mRNA ratios for bax / bcl -2 and bax / survivin were also not informative across tumor types. Of the genes examined, only p21 gave a predictable response 24 hours after p53 gene therapy and therefore, p21 expression may be useful for confirming SCH58500 activity in human tumor biopsies.
P
53 is a DNA -binding protein that acts as a transcription factor to control the expression of proteins involved in the cell cycle. 1, 2 In response to DNA damage, p53 protein accumulates in the cell nucleus, causing cells to undergo cell cycle arrest and DNA repair or apoptosis (programmed cell death ). 3 Functional inactivation of p53 can occur by several mechanisms including direct genetic mutation, binding to viral oncoproteins or cellular factors ( e.g., MDM-2 ) , or alteration of the subcellular localization of the protein.
1,2 Although p53 is not essential for normal development, p53``knock -out'' mice are susceptible to tumors early in life. 4 Mutations in p53 have been reported in a majority of clinical cancers, and it has been estimated that p53 function is altered in at least half of all human malignancies. 1, 2 p53 gene therapy for cancer is currently undergoing clinical trials using SCH58500 ( ACN53 ). SCH58500 consists of a replication-deficient, type 5 adenovirus (Ad ) vector expressing human wild -type p53 tumor suppressor. 5 In preclinical models, SCH58500 has therapeutic efficacy against a wide range of human tumor types containing nonfunctional p53, both in vitro and in vivo. 5 ± 13 However, it is more difficult to prove activity in human patients. Typical preclinical methods for investigating the expression of p53-regulated and downstream apoptosis genes after p53 gene therapy involve doing Western blots to assess the extent of protein phosphorylation or changes in protein levels, or Northern blots to assess relative mRNA levels. This is a relatively easy endeavor when tumor cell lines or xenografts in mice are used to supply tissues for analyses. Unfortunately, human clinical samples are usually available in very limited quantities. Often, samples will consist of less than 100 mg, fine needle aspiration, or ascites pellet. This limited supply of human tissue must be subjected to a battery of very sensitive tests in order to prove the activity of a novel therapeutic. For this reason, we undertook the development and validation of real -time quantitative reverse transcriptase polymerase chain reaction ( RT-PCR ) assays. This methodology allows the quantitation of mRNA levels for up to 50 genes in a single 100 -mg biopsy sample.
In general, cancers containing nonfunctional p53 tumor-suppressor protein are less sensitive to chemotherapy. 14 Many anticancer agents can induce apoptosis via p53 -dependent (cisplatin, doxorubicin, 5 -fluorouracil ) or p53 -independent ( paclitaxel ) pathways. 14 ± 16 In theory, the introduction of wild -type p53 into cells with nonfunctional p53 protein should enhance their sensitivity to most chemotherapeutics. Preclinical data support this theory. 7, 10, 12 In addition, several reports have suggested that even drugs, which induce apoptosis independent of p53, can synergize with SCH58500 through multiple mechanisms. 12, 17 Results from early clinical trials using SCH58500 by itself support optimism for the future of this therapeutic approach to cancer treatment. 18 However, most later stage trials are designed to compare traditional chemotherapy with chemotherapy plus p53 gene therapy. For all these reasons, it is important to study possible interactions between SCH58500 and chemotherapeutic drugs. Paclitaxel was chosen for the study reported here due to its extensive use as a first -line therapy in ovarian cancer, its synergy with SCH58500 in preclinical cancer models, 12 and its induction of p53-independent apoptosis, which might result in a``lowered threshold'' for tumor cell death.
In cells with wild -type p53, expression of p53 is rapidly up -regulated after radiation -induced DNA damage, followed by p53 -induced transcriptional activation of genes such as p21 and bax. 19 ± 22 p21 is thought to induce G1 arrest through its inhibitory effects on the activity of cyclindependent kinases. 21 Up -regulation of BAX activity can activate caspases, accelerating cell apoptosis. 23 Although an effect of p53 regulation on bcl -2 has not been directly demonstrated, BCL -2 function can be modified by BAX. 24 Expression of survivin, a member of the inhibitor of apoptosis gene family, has been found in most cancers examined, including human lung adenocarcinoma, 25 highgrade lymphoma, 25 colorectal cancer, 26 and gastric cancer. 27 However, survivin is generally not expressed in normal adult tissues. 25 Although a direct link between p53 activity and survivin expression has not been conclusively established, survivin can inhibit apoptosis induced by paclitaxel 25 and BAX. 28 survivin can also directly inhibit caspase -3 activity. 28 Moreover, a correlation has been reported between accumulation of mutant p53 protein and increased expression of survivin. 27 In this paper, we developed sensitive, real -time quantitative RT-PCR assays to monitor exogenous p53 expression and it capability to mediate responses in``d ownstream'' genes in established tumors, rather than in cultured cells.
MATERIALS AND METHODS

Human tumor cell lines
All cell lines were obtained from ATCC (Rockville, MD MDA -MB -231 mammary tumor cells carry an Arg -toLys mutation in codon 280 of the p53 gene and express mutant p53. 29 MDA -MB -468 mammary tumor cells carry an Arg-to -His mutation in codon 273 of the p53 gene and express mutant p53. 29 DU -145 prostate tumor cells carry two mutations on different chromosomes, a Pro -to -Leu mutation in codon 223 and a Val -to -Phe mutation in codon 274. 30 They express mutant p53. SK -OV-3 ovarian tumor cells are p53-null. 33 PA -1 ovarian tumor cells carry a silent mutation and are p53 wild -type. 31 MIAPaCa2 pancreatic tumor cells carry an Arg-to -Trp mutation in codon 248 of the p53 gene, an Arg -to -His mutation in codon 273 of the p53 gene, and express mutant p53. 32 
Recombinant Ads
Construction and propagation of human wild -type p53 Ad ( SCH58500; ACN53 ) and Escherichia coli -galactosidase adenovirus ( -gal Ad; rAd --gal ) have been described previously. 5 The Empty Ad construct is the same as SCH58500 except that the p53 transgene has been deleted. The concentration of total viral particles ( PN ) in SCH58500 batches was determined by measuring absorption at 260 nm. 33 The concentration of total PN in control vector batches was determined by Resource Q Anion Exchange HPLC assay. 34 Infectious PN was determined by measuring the concentration of viral hexon protein positive 293 cells after a 48-hour infection period. 33 CIU is defined as cellular infectious units. 35 Ads were administered in phosphate buffer (20 mM NaH 2 PO 4 , pH 8.0, 130 mM NaCl, 2 mM MgCl 2 , 2% sucrose) .
Tumor therapy in vivo C.B.17 /ICR -SCID mice were purchased from Taconic Farms ( Germantown, NY ). All mice were maintained in a VAF barrier facility. Animal procedures were performed in accordance with the rules set forth in the NIH Guide for 17 Ad particles are relatively large and have limited diffusion through solid tumors. Intratumoral injections often result only in infection of cells within a few millimeters of the needle track. Hence, two intratumoral injections result in a higher percentage of the entire tumor being infected than a single injection. The time interval of 3 ± 4 hours gives the puncture site in the skin time to seal. When two injections are given in a rapid sequence, most of the virus solution from the second injection will leak out the skin puncture from the first injection site. Some mice also received an intraperitoneal dose of 10 mg /kg paclitaxel. Twenty -four hours later, tumors were harvested and cut in half. Half of each tumor was flash-frozen for RNA extraction and half was fixed in 10% buffered formalin ( Fisher Scientific, Springfield, NJ ) for immunohistochemistry. There were five tumors (five mice) per treatment group, except for MDA -MB -468 where there were four tumors per treatment group.
Quantification of gene expression using real -time quantitative RT -PCR assays
Total RNA was extracted from approximately 100 mg of each tumor using Tri -Reagent ( Molecular Research Center ) per manufacturer's protocol. Total RNA was treated with DNase I (Boehringer-Mannheim, Indianapolis, IN ) to remove residual DNA. The complete removal of DNA in all RNA samples was confirmed using human glyceraldehyde -3-phosphate -dehydrogenase (gapdh ) PCR. RNA concentrations were determined using OD 260/ 280 absorbance ratios and approximately 0.1 g of total RNA was used for each RT-PCR reaction. Quantification of gene expression was performed using real time quantitative RT-PCR, 37 ,38 which uses the 5 H nuclease activity of Taq polymerase to detect PCR amplicons. Briefly, in addition to primers, a target sequence± specific oligonucleotide probe labeled with a reporter fluorescent dye [FAM ( 6-carboxyfluorescein ) ] at the 5 -H end and a quencher fluorescent dye TAMRA (6 -carboxy -tetramethyl -rhodamine ) at the 3 H end were added to the PCR reaction. When the probe is intact, the fluorescence emission of the reporter is quenched due to the physical proximity of the reporter and quencher fluorescent dyes. The resulting relative increase in reporter fluorescent dye emission is monitored in real time during PCR amplification using a sequence detector, the 7700 Sequence Detector ( PE Applied BioSystems, Foster City, CA ). Assays used the Taqman EZ RT-PCR kit (PE Applied BioSystems ) . RT-PCR was performed in a total volume of 50 L containing 1.0 L of total RNA extracted from tumors or cells, 300 mM each of dATP, dGTP or dCTP, and 600 mM of dUTP, 10 U of rTth DNA polymerase, 0.5 U of AmpErase UNG to eliminate carryover PCR product contamination, 10 mM of each primer, and 10 mM of probe ( Table 1 ) . The following thermal cycler parameters were optimized for p53 transgene detection: 2 minutes at 508C, 30 minutes at 608C, 10 minutes at 958C, followed by 40 cycles of 20 seconds at 958C and 1 minute at 618C. The human gapdh housekeeping gene was quantified by using control reagent (PE Applied BioSystems ) . The sequence of the oligonucleotides used in the above assays is listed in Table 1 . Sequences were from Refs.. 25 ,39 ± 41 Levels of p53 DNA and p53 mRNA in the SCH58500 paclitaxel groups were compared using an 
Generation of cRNA standards for real -time quantitative RT -PCR assays
Purified rAd -p53 viral DNA was used as a template to amplify a 279 -bp region containing T7 sequence of cDNA using a 5 H primer to the CMV sequence and 3 H primer to the p53 transgene sequence. In the case of the p21, bax, and bcl -2 genes, which contain no T7 regions, human genomic DNA extracted from MDA -MB -468 cells was used to generate the first strand cDNAs, < 150 bp PCR products, to be used as templates to generate T7 -containing cDNA. T7 sequence was incorporated into the first strand cDNAs using PCR strategy. The conditions for amplification were 10 minutes at 958C to activate TaqGold polymerase (PE Applied BioSystems), followed by 15 seconds at 958C, and 1 minute at 608C for 30 cycles. The PCR products in each step were confirmed by electrophoresis on 10% (wt /vol ) polyacrylamide gels and visualized by staining the gels with ethidium bromide (Sigma ). Amplified cDNA was purified using the QIAquick PCR purification kit ( Qiagen, Valencia, CA ) and used as a template for in vitro transcription. In vitro transcription was performed using the AmpliScribe T7 Transcription kit ( Epicentre Technologies, Madison, WI ) . The transcribed cRNA was treated with DNase I to remove residual DNA and further purified using the RNeasy kit ( Qiagen ) . The cRNA concentration was determined by absorbance at OD 260 nm. All procedures were performed per the manufacturers' protocols when reagent kits were used in the study.
p53 and p21 immunohistochemistry
Five -micrometer, formalin -fixed, paraffin-embedded sections were deparaffinized and rehydrated. Sections were treated with ethanol /acetic acid (2:1 ) at À 208C for 10 minutes and antigens were retrieved by microwaving in 0.01 M, pH 6.0 citric buffer for 10 minutes. Endogenous peroxidase activity was quenched with 1.5% hydrogen peroxide in cold ethanol for 10 min. The sections were then blocked with normal rabbit serum ( Novocastra, Newcastle upon Tyne, UK ). The primary antibodies used were mouse antihuman p53 (cat. no. NCL -p53 -Paraffin, Novocastra ) and mouse antihuman p21 (cat. no. 15091A, PharMingen, San Diego, CA ). The incubation time for primary antibodies was 1 hour. For the negative control, primary antibodies were substituted with nonimmune mouse immunoglobulin ( PharMingen ) diluted to match the primary antibody protein concentration. Sections were then incubated with biotinylated rabbit antimouse antibody ( 1:500; Novocastra ) for 30 minutes. Specific antibody binding was detected by ABC reagent ( avidin /biotinylated horseradish peroxidase; Novocastra) . Diaminobenzadine chromogen (Vector Laboratory, Burlingame, CA ) was used for color development. The slides were then counterstained with hematoxylin (Sigma) , washed in water once, 95% ethanol 3Â for 30 seconds each wash, 100% ethanol 2Â for 1 minute each wash, and Clear Rite ( Richard -Allen, Kalamazoo, MI ) 2Â for 1 minute each wash. Coverslips were mounted using Permount (Fisher Scientific ).
RESULTS
Real -time quantitative RT -PCR assays
Real-time quantitative RT-PCR assays were developed to measure expression of exogenous p53, p21, bax, bcl -2, survivin, and gapdh. Human -specific primers and probes were used to detect gene expression in human tumor xenografts from SCID mice treated with various combinations of vehicles, recombinant Ads, and /or paclitaxel. For measuring transgenic p53 mRNA, a primer pair specific to SCH58500 was used, which avoided detection of endogenous p53 mRNA. The cRNA standards used in this study demonstrated good linearity. Representative cRNA standard curves are shown in Figure 1A . survivin was quantified using a serially diluted total RNA from human PA -1 cells ( data not shown ). The relative quantification unit for survivin ( MEQ ) is an arbitrary number assigned based on dilution factors. The reproducibility of the realtime RT-PCR assay for p21 is shown in Figure 1B . The assay was performed using six serially 10 -fold diluted cRNA samples on three different dates. The assays for transgenic p53, bax, bcl -2, survivin, and gapdh had similar performance parameters (data not shown ).
Baseline mRNA levels in vehicle control tumors
It is not scientifically valid to compare gene expression in different treatment groups between tumor types because ( 1) the recombinant Ads were given intratumorally, allowing for limited diffusion of virus particles; and (2 ) the different tumor types were of different sizes when harvested, such that a different total percentage of tumor cells was infected in each group. Only when all cells within a tumor were exposed equally at treatment were comparisons between tumor types 5 . In addition, the variation in no treatment gapdh expression within the same type of tumor was very tight ( 9± 12% ) . This`h ousekeeping'' gene is often used for normalization of gene expression data. However, in our experiments, various treatments caused significant changes in the cellular content of gapdh mRNA (data not shown) . For example, in MDA -MB -231 and SK -OV-3 tumors, paclitaxel enhanced gapdh expression by 9.5 -and 6.6-fold, respectively. Therefore, all expression levels were normalized to tumor sample weight instead.
Quantitation of p21 mRNA in vehicle control tumors revealed a range of baseline expression from 2.3Â10 6 0.2 Â10 6 to 15.8Â10 6 4.7Â10 6 mRNA copies / mg tumor ( mean SEM ) with MDA -MB -231> DU -145 >MIAPa-Ca2 > PA -1 >SK -OV-3> MDA -MB -468 ( Fig 2) . The range of bax mRNA levels was much smaller, from 1.9Â10 7 0.2Â10 7 to 4.4Â10 7 1.5Â10 7 mRNA copies / mg tumor ( Fig 3 ) . Levels of bcl -2 mRNA ranged from 1.5Â10 4 0.7Â10 4 to 1.6Â10 5 0.9Â10 5 mRNA copies /mg tumor (Fig 3 ) . bax /bcl -2 ratios ranged from a low of 119 10 (SK -OV-3 ) to a high of 4128 1536 ( PA -1) .
p53 and p21 gene expression in treated tumors
We next investigated whether SCH58500 treatment produced pharmacological levels of wild -type p53 in tumors with subsequent changes in p21, bax, bcl -2, and survivin expression. In normal cells, wild -type p53 has been reported to up -regulate p21 and bax at the transcriptional level, 19 ± 22 and reconstitution of wild -type p53 expression in tumor cells may enhance their sensitivity to chemotherapeutic agents. 14 To determine whether paclitaxel influenced the regulation of p53 -responsive genes, we analyzed gene expression in tumors treated with recombinant Ads in combination with paclitaxel. We had previously shown that SCH58500 suppressed the growth of these human tumor xenografts and that combination therapy with paclitaxel had enhanced efficacy over single agent treatment. 7, 11, 12 Only tumors injected with SCH58500 had detectable levels of exogenous p53 DNA and mRNA (Fig 4 ) . Combination therapy with SCH58500 and paclitaxel had no effect on p53 DNA or p53 mRNA levels in any of the tumor types examined (P >.05).
Elevated levels of p21 gene expression were observed in five of six tumors treated with SCH58500 (P .075 ). Only p53 wt PA -1 tumors failed to respond to any treatment with increased p21 mRNA (P > .05, F =1.39 for all treatment groups ). In fact, paclitaxel with or without Ad vector lowered p21 mRNA levels below those of vehicle -treated PA -1 tumors (P .06 ). Figure 2 summarizes the gene expression data for p21. Elevated levels of p21 mRNA were evident in three of the tumors exposed to both SCH58500 and paclitaxel simultaneously, compared to vehicle control ( P .05 ). Treatment with Empty Ad or paclitaxel alone generally had no effect on p21 mRNA levels (P >.05), except for MIAPaCa2 tumors where paclitaxel enhanced p21 expression ( Fig 2C; P .0003) . In MDA -MB -468 tumors ( Fig 2A ) , levels of p21 mRNA rose 11 -fold after SCH58500 (P .0072 ) and 17.5 -fold (P .0002 ) after combination therapy with SCH58500 and paclitaxel, compared to tumors treated with control vector. A 6± 7 ±fold increase was observed in MDA -MB -231 tumors exposed to SCH58500 with or without paclitaxel, compared to tumors exposed only to control vector ( Fig 2B; P .046) . A 10 -fold p21 mRNA increase was also evident in SKOV-3 tumors treated with SCH58500, compared with control virus treatment alone (Fig 2E; P .05 ) . The p53 -induced p21 up -regulation was marginal ( < 3-fold ) in MiaPaCa2 ( Fig  2C ) and DU145 tumors (Fig 2D ) . Interestingly, in DU -145 and SK -OV-3 tumors, paclitaxel suppressed the p53-induced rise in p21 mRNA 4-fold, compared to tumors dosed with SCH58500 alone.
Apoptosis -related gene expression in treated tumors
Introduction of wild -type p53 can induce apoptosis in cancer cells with altered p53 function. 10 Bcl -2 family members served as critical regulators of apoptosis. 42 In particular, BAX, BCL -2, and the ratio between these two proteins have been implicated in the induction or suppression of apoptosis. 43 Therefore, we investigated the predictive value of bax and bcl -2 mRNA changes after apoptosis -inducing therapies in vivo. There was no consistent pattern to the alterations in bax gene expression observed in tumors treated with SCH58500 alone, paclitaxel alone, or both agents. In general, SCH58500 had no effect on bax mRNA levels, although bax mRNA was increased in MIAPaCa2 tumors (Fig 3; P .001 ) and decreased in PA -1 tumors (P .037) , compared to tumors dosed with vehicle. In PA -1 tumors, decreased bax mRNA was attributable to the Ad vector and not to the p53 transgene. In general, paclitaxel also had no effect on bax levels, except for small ( < 3 -fold ) changes in MIAPaCa2 tumors (increase; P .014 ) and PA -1 tumors ( decrease; P .037 ). There was no consistent pattern to the alterations in bcl -2 gene expression observed in tumors treated with SCH58500 alone, paclitaxel alone, or both agents ( Fig 3 ) . SCH58500 had no significant effect on bcl -2 mRNA levels, except in MDA -MB -231 tumors where bcl -2 levels rose ( P .004) and MDA -MB -468 tumors where bcl -2 fell ( P .0004 ) , compared to tumors treated with vehicle. Interestingly, paclitaxel suppressed the bcl -2 mRNA rise induced by SCH58500 in MDA -MB -231 tumors (P .045 ). In SK -OV-3 and MDA -MB -468 tumors, the Ad vector suppressed bcl -2 mRNA ( P .021) , whereas paclitaxel had a marginal effect only in MDA -MB -468 tumors (P .067) . The combination of paclitaxel and Ad vector down -regulated bcl -2 expression in DU -145 and SK -OV-3 tumors (P .019 ). PA -1 and MIAPaCa2 tumors failed to respond to any treatment with changes in bcl -2 mRNA (P < 05, F = 0.79; P >.1, F = 0.362, respectively, for all treatment groups ), although there was a trend toward decreased bcl -2 mRNA.
There was no consistent pattern to the alterations in bax/ bcl -2 mRNA ratios. SCH58500 caused an increase in this ratio in two tumors ( SK -OV-3, MDA -MB -468; P .065) , a decrease in one tumor ( MDA -MB -231; P .019) , and no change in the other tumors ( P> .05 ). Ad vector or paclitaxel generally had no effect on the bax /bcl -2 mRNA ratios, except in SK -OV-3 tumors where control vector increased the ratio (P .013 ) and MDA -MB -231 tumors where paclitaxel decreased the ratio (P .027 ). Only in MDA -MB -468 tumors did the p53 transgene affect the bax /bcl -2 mRNA ratio ( P .003) and paclitaxel did not alter this response ( P .009 ). Figure 3 shows the quantitative analysis for survivin expression. survivin mRNA levels were not significantly affected by Ad vector or paclitaxel ( P> .05 ). SCH58500 caused an elevation in survivin mRNA in MIAPaCa2 and MDA -MB -231 tumors (P .036 ), with a similar trend in DU -145 tumors. There was a marginal suppression of survivin gene expression by SCH58500 in PA -1 tumors ( P .073 ) with a trend toward suppression in SK -OV-3 and MDA -MB -468 tumors.
p53 and p21 protein expression Figure 5 shows representative tumor sections assayed for cellular expression of p53 and p21 proteins. In p53 null SK -OV-3 tumors, nuclear-localized p53 protein was observed in cells proximal to the site of intratumoral SCH58500 injection, but not in SK -OV-3 tumor cells in other treatment groups (panels A and B ) . Cells in the area of SCH58500 injection also had elevated levels of nuclear-localized p21 protein expression (panels C and D ) . As expected, tumors expressing mutant p53 (MDA -MB -468 and MIAPaCa2 ) were positive for p53 expression by immunohistochemistry ( data not shown) . Tumor cells in proximity to the site of intratumoral SCH58500 injection also expressed high levels of p21 protein ( panels E and F ) . Surprisingly, in both p53 mut tumor types assayed, p21 was localized more to the cytoplasmic than to the nuclear compartment. In p53 wt PA -1 tumors, scattered cells in all treatment groups had variable levels of p21 protein (panels G and H ). SCH58500 treatment failed to induce an elevation in p21 protein in PA -1 tumors.
DISCUSSION
Ad -mediated p53 gene therapy for cancer is currently undergoing clinical trials using SCH58500 (ACN53) . SCH58500 is a replication-deficient, type 5 Ad expressing human wild -type p53 tumor suppressor. 5 In preclinical models, SCH58500 has therapeutic efficacy against a wide range of human tumor types containing nonfunctional p53, both in vitro and in vivo.
5 ± 13 However, it is more difficult to prove activity in human patients than in preclinical models. Typical preclinical methods for investigating the expression of p53 -regulated and downstream apoptosis genes require relatively large supplies of treated tissue. Unfortunately, human clinical samples are usually available in very limited quantities. Often, samples consist of a few hundred milligrams from a tumor biopsy, fine needle aspirate, or ascites pellet. In addition, the cellular response to p53 gene therapy may vary depending on the tissue of origin, the in vivo microenvironment, and the genetic phenotype. For these reasons, we undertook the development and validation of real -time quantitative RT-PCR assays. This technique permits the quantitation of mRNA levels of up to 50 genes in a single 100-mg biopsy sample.
Aside from the suppressive effects of p53 gene therapy on tumor growth through induction of apoptosis, little is known about the biological behavior of the exogenous p53 once it becomes active in tumors. Several publications have reported an elevation in p21 protein levels after p53 gene therapy, 10 but the influence of chemotherapy on this biological response has not previously been examined. Paclitaxel has been shown to affect gene expression in cells. 44 ± 47 Some paclitaxel activities include stimulation of p53 and p21 protein levels in p53 wt A549 lung tumor cells, 47 suppression of bcl -xL mRNA and protein in p53 wt LNCaP prostate tumor cells, 44 and possibly paclitaxel binding and inactivation of anti -apoptotic BCL -2 protein. 46 The effects of paclitaxel on gene expression seem to be independent of its ability to stabilize microtubules because the closely related analog, docetaxel, did not affect gene expression in the RAW 264.7 murine macrophage cell line. 45 In our study, we investigated how exogenous wild -type p53, Ad vector, and paclitaxel affect the expression of the downstream effector gene p21 and the apoptosis -related genes bax, bcl -2, and survivin. In order to most closely mimic the clinical situation, tumor xenografts were exposed to intratumoral Ad and systemic paclitaxel.
Real -time quantitative RT-PCR allows for quantitation of gene expression in large numbers of samples with unparalleled precision. 37 We developed real -time quantitative RT-PCR assays using in vitro ±transcribed cRNAs as standards. Because cRNA not only shares the same primer pair and probe, but also the same amplicon sequence with the target gene, the efficiency of both reverse transcription and PCR is very comparable to the target gene using this technique. This eliminates discrepant amplification efficiency between the standard and the target gene. Normalization of a target gene's expression to the expression of a housekeeping gene is a generally accepted practice. gapdh is frequently used for this purpose because of the widely accepted assumption that the transcriptional levels of this gene are not affected by different treatments regimes. This assumption has been recently challenged 48 and indeed, our experiments demonstrate that paclitaxel changes gapdh gene expression in some tumors. In fact, bax expression showed less fluctuation than gapdh expression. Bax mRNA levels thus served as an internal control to show that the quality and amount of RNA assayed in different samples were comparable. Because of gapdh variability, our gene expression results were normalized to tumor weight instead of gapdh mRNA.
The ability of p53 to up -regulate p21 transcription has been demonstrated in numerous experiments. 10 In our study, p53
null SK -OV-3 tumors had nuclear-localized p53 protein in cells proximal to the site of intratumoral SCH58500 injection. These same cells also expressed high levels of nuclear-localized p21 protein. Surprisingly, p21 protein was primarily located in the cytoplasm of p53 mut MDA -MB -468 and MIAPaCa -2 cells. All five p53 mut tumors had elevated p21 mRNA after SCH58500 treatment. These results are consistent with most in vitro studies. However, we did not find a correlation between up -regulation of bax and bcl -2 mRNA expression and exogenous expression of wild -type p53. Up -regulation of p21 mRNA after p53 gene therapy with or without paclitaxel chemotherapy indicates that SCH58500 expressed functional and sufficient levels of p53 to elicit biological responses in these tumors. Thus, the failure of p53 -mediated up -regulation of bax and bcl -2 in these tumors cannot be explained by a deficiency in functional p53 expressed from SCH58500. Wild -type p53 is a direct transcriptional activator of the bax gene and, as a consequence of bax expression, bcl -2 mRNA and protein levels decrease in human H358 lung cancer cells, Saos-2 osteosarcoma cells, HeLa cervical cancer cells, and Tsuprl prostate cancer cells. 20 The lack of correlation between bax, bcl -2, and p53 expression observed in our study may be due to: (1 ) cellular context; (2 ) genetic changes; or ( 3) microenvironmental differences between cells cultured in vitro and tumors growing in vivo. There are considerable cell type and tissue type differences in the spectrum of genes regulated by p53. 49, 50 p53 -dependent apoptosis can be mediated via Bcl -2, Fas /Apo -1, and /or TNFR family members. The diversity of molecular mechanisms attributed to these genes and their downstream effectors illustrates the complexity of apoptosis. Heterogeneous genetic changes in tumor cells can influence cellular response to wild -type p53 reintroduction. For instance, DU -145 cells have undetectable levels of BCL -2 and BAX proteins. 51 In addition, overexpression of oncogenes such as myc, 52 raf, or v-src 53 can influence the p53-dependent apoptotic pathway. It is likely that the difference in transduction efficiency between cell culture and established tumors caused by the limited diffusion ability of virus particles in solid tumors may also contribute to this discordance. The effective intracellular concentration of p53 required for induction of p21, bax, and bcl -2 expression is not currently known and may differ between cell types. The dose and treatment time used in this study have been shown to be able to induce p21 transcription; however, these conditions may not be adequate to observe a change in bax and bcl -2 gene expression levels.
Expression of survivin has been found in most cancers examined, including human lung adenocarcinoma, 25 highgrade lymphoma, 25 colorectal cancer, 26 and gastric cancer. 27 However, survivin is generally not expressed in normal adult tissues. 25, 27 Although a direct link between p53 activity and survivin expression has not been proven, SURVIVIN protein can inhibit apoptosis induced by paclitaxel 25 and BAX. 28 Also, survivin expression correlated with detection of mutant p53 and elevated BCL -2 protein by immunohistochemistry in primary gastric cancers (n =174 ). 27 SURVIVIN can also directly inhibit caspase -3 activity. 28 In our study, SCH58500 tended to stimulate survivin mRNA levels in half the tumor lines and to suppress it in the other half. The ratios of bax mRNA / survivin mRNA were generally uninformative.
In Nielsen et al, 12 synergistic interactions between SCH58500 and paclitaxel were demonstrated in a panel of human tumor cell lines in vitro. These effects were mediated, at least in part, by the unexpected ability of low nanomolar concentrations of paclitaxel to enhance Ad transduction of tumor cells in vitro. In other words, more tumor cells in the monolayer were infected with SCH58500 in vitro and exposed to high levels of wild -type p53 protein when paclitaxel``sensitized'' them to transduction by recombinant Ad. This effect can be attributed to a paclitaxel -induced increase in the number of CAR1 receptors on tumor cell membranes ( Xie, unpublished ). Grace et al 17 reported that co -administration of paclitaxel with SCH58500 had no effect on the depth of Ad penetration into solid SK -OV-3 tumor nodules in SCID mice, indicating that paclitaxel did not make the surface layer of the tumors more``porous'' to enhance virus particle diffusion. However, combination therapy did cause an elevation in the total number of tumor cells within the solid nodules undergoing apoptosis, compared with paclitaxel treatment alone; this result is still unexplained. In the current study, paclitaxel muted the p53-mediated induction of p21 expression in DU -145 and SK -OV-3 tumors. Expression levels of bax and bcl -2 were also reduced in DU -145 and SK -OV-3 tumors treated with both paclitaxel and SCH58500 as compared to tumors treated with SCH58500 alone.
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